SLC5A2 and autosomal dominant polycystic kidney disease: Patients with autosomal dominant polycystic kidney disease (ADPKD) were excluded from participation in prior SGLT2 outcome trials, as it is known that SGLT2 inhibitors increase vasopressin and that vasopressin receptor antagonists are renoprotective in this patient population [23].